Begin main content

Find a Review (pCODR)

Updates on pCODR drug reviews underway are regularly posted to this page.

Completed reviews are posted on cadth.ca. They are searchable and freely available to anyone to use, download, or print for non-commercial and personal use, or private research and study, provided you do not modify them and appropriate credit is given to CADTH.

You can also find more general updates about pCODR on the pCODR Communication Updates page.

Export to CSV
Brand Name Generic Name Tumour Type / Indication Review Status Last Updated
Adcetris Brentuximab vedotin Lymphoma
Systemic Anaplastic Large Cell Lymphoma
Notification to Implement Issued December 20, 2013
Arzerra Ofatumumab Leukemia
Chronic Lymphocytic Leukemia
Notification to Implement Issued February 23, 2015
Giotrif Afatinib Lung
Advanced Non Small Cell Lung Cancer
Notification to Implement Issued July 25, 2014
Kadcyla Trastuzumab emtansine Breast
Metastatic Breast Cancer
Notification to Implement Issued January 27, 2014
Nexavar Sorafenib Endocrine
Metastatic Progressive Differentiated Thyroid Carcinoma (DTC)
Notification to Implement Issued September 29, 2015
Xalkori Crizotinib Lung
First Line ALK Positive Advanced NSCLC
Notification to Implement Issued August 6, 2015
Zytiga Abiraterone acetate Genitourinary
Metastatic Castration Resistant Prostate Cancer
Notification to Implement Issued November 6, 2013
Votrient Pazopanib hydrochloride Genitourinary
Metastatic Renal Cell Carcinoma
Notification to Implement Issued Resubmission Complete January 20, 2012
Tykerb (in combination with Letrozole) Lapatinib Breast
Metastatic Breast Cancer
Notification to Implement Issued July 22, 2013
Revlimid Lenalidomide Myeloma
Multiple Myeloma
Notification to Implement Issued November 6, 2013
Treanda (in combination with rituximab) Bendamustine hydrochloride Leukemia
Chronic Lymphocytic Leukemia
Withdrawn September 26, 2014
Jakavi Ruxolitinib Other
Polycythemia vera
Notification to Implement Issued March 18, 2016
Blincyto Blinatumomab Leukemia
Acute Lymphoblastic Leukemia
Notification to Implement Issued April 18, 2016
Unituxin Dinutuximab Neurological
Neuroblastoma
Under Review October 16, 2018
Keytruda Pembrolizumab Lung
Non-Squamous NSCLC
Under Review October 9, 2018
Blincyto Blinatumomab Leukemia
Minimal residual disease (MRD)-positive B-cell precursor acute lymphoblastic leukemia (ALL)
Withdrawn October 16, 2018
Darzalex Daratumumab Myeloma
Multiple Myeloma
Notification to Implement Issued December 16, 2016
Onivyde Nanoliposomal Irinotecan Gastrointestinal
Metastatic Pancreatic Cancer
File-Closed Not Submitted December 2, 2016
Ninlaro Ixazomib Myeloma
Multiple Myeloma
Notification to Implement Issued July 17, 2017
Opdivo Nivolumab Head and Neck
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Notification to Implement Issued September 18, 2017
Opdivo Nivolumab Lung
Non-Small Cell Lung Cancer
Notification to Implement Issued August 15, 2016
Adcetris Brentuximab vedotin Lymphoma
Hodgkin Lymphoma (post-ASCT consolidation)
Withdrawn July 7, 2016
Vectibix Panitumumab Gastrointestinal
Left Sided Metastatic Colorectal Cancer
Notification to Implement Issued April 16, 2018
Lynparza (Resubmission) Olaparib Gynecology
Ovarian Cancer
Notification to Implement Issued October 5, 2017
Xalkori Crizotinib Lung
ROS1-positive advanced Non-Small Cell Lung Cancer
Under Review November 14, 2018
Gazyva Obinutuzumab Lymphoma
Follicular Lymphoma (previously untreated)
Notification to Implement Issued November 16, 2018
Opdivo Nivolumab Gastrointestinal
Hepatocellular Carcinoma (HCC)
Under Review November 16, 2018
Adcetris Brentuximab vedotin Lymphoma
Hodgkin Lymphoma
Notification to Implement Issued September 17, 2013
Bosulif Bosutinib Leukemia
Chronic Myeloid Leukemia
Notification to Implement Issued June 4, 2015
Perjeta Herceptin Combo Pack Pertuzumab Breast
Metastatic Breast Cancer
Notification to Implement Issued August 20, 2013
Avastin (with capecitabine) Bevacizumab Gastrointestinal
Metastatic Colorectal Cancer
Notification to Implement Issued November 13, 2015
Halaven Eribulin Mesylate Breast
Metastatic Breast Cancer
Notification to Implement Issued August 20, 2012
Votrient Pazopanib hydrochloride Genitourinary
Metastatic Renal Cell Carcinoma
Notification to Implement Issued Original Submission Complete September 17, 2013
Velcade Bortezomib Myeloma
Multiple Myeloma
Notification to Implement Issued April 11, 2013
Treanda Bendamustine hydrochloride Leukemia
Chronic lymphocytic leukemia (Relapsed/ Refractory)
Notification to Implement Issued December 14, 2012
Stivarga (CRC) Regorafenib Gastrointestinal
Metastatic Colorectal Cancer
Notification to Implement Issued December 2, 2013
Xtandi Enzalutamide Genitourinary
First Line Metastatic Castration-Resistant Prostate Cancer
Notification to Implement Issued July 31, 2015
Avastin Bevacizumab Gynecology
Cervical Cancer
Notification to Implement Issued April 8, 2015
Tafinlar & Mekinist in combo Dabrafenib & Trametinib in combo Lung
Non-Small Cell Lung Cancer
Notification to Implement Issued November 17, 2017
Imbruvica Ibrutinib Lymphoma
Mantle Cell Lymphoma
Notification to Implement Issued August 4, 2016
Zydelig Idelalisib Lymphoma
Follicular Lymphoma
Notification to Implement Issued October 17, 2016
Vectibix Panitumumab Gastrointestinal
Metastatic Colorectal Cancer
Notification to Implement Issued December 18, 2015
Afinitor Everolimus Endocrine
Neuroendocrine tumours of Gastrointestinal or Lung origin
Notification to Implement Issued December 16, 2016
Kyprolis Carfilzomib Myeloma
Multiple Myeloma (relapsed)
Notification to Implement Issued April 17, 2017
Lutathera Lutetium Lu 177 dotatate Gastrointestinal
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Under Review October 10, 2018
Erbitux Cetuximab Gastrointestinal
Left Sided Metastatic Colorectal Cancer
File-Closed Not Submitted April 26, 2018
Bavencio Avelumab Skin & Melanoma
metastatic Merkel Cell Carcinoma
Notification to Implement Issued April 6, 2018
Dacomitinib TBD Lung
Non-Small Cell Lung Cancer
Under Review October 9, 2018
Alecensaro Alectinib Lung
Locally advanced or metastatic non-small cell lung cancer (second line)
Notification to Implement Issued April 16, 2018
Ibrance (with Faslodex) Palbociclib (with Fulvestrant) Breast
Advanced or Metastatic Breast Cancer
Under Review October 16, 2018
Ninlaro Ixazomib Myeloma
Multiple Myeloma (2nd-beyond)
Pending November 2, 2018
Keytruda Pembrolizumab Skin & Melanoma
Melanoma Adjuvant Treatment
Pending November 9, 2018
Tafinlar & Mekinist in combo Dabrafenib & Trametinib in combo Skin & Melanoma
Melanoma Adjuvant Therapy
Under Review November 14, 2018
Perjeta-Herceptin Combo Pack Pertuzumab-Trastuzumab Combo Pack Breast
Early Breast Cancer
Under Review November 16, 2018
Afinitor Everolimus Gastrointestinal
Pancreatic neuroendocrine tumours
Notification to Implement Issued September 18, 2012
Avastin Bevacizumab Gynecology
Ovarian Cancer
Notification to Implement Issued June 26, 2015
Erbitux Cetuximab Gastrointestinal
Metastatic Colorectal Cancer
Notification to Implement Issued January 27, 2014
Inlyta Axitinib Genitourinary
Metastatic Renal Cell Carcinoma
Notification to Implement Issued March 22, 2013
Xtandi Enzalutamide Genitourinary
Metastatic Castration Resistant Prostate Cancer
Notification to Implement Issued August 8, 2013
Perjeta or Perjeta-Herceptin Combo Pack Pertuzumab Breast
Neoadjuvant Breast Cancer
Notification to Implement Issued September 29, 2015
Imbruvica Ibrutinib Leukemia
Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (previously treated)
Notification to Implement Issued March 20, 2015
Sutent Sunitinib malate Gastrointestinal
Pancreatic neuroendocrine tumours
Notification to Implement Issued May 18, 2012
Treanda Bendamustine hydrochloride Leukemia
Chronic lymphocytic leukemia (First Line)
Notification to Implement Issued March 6, 2013
Votrient Pazopanib Hydrochloride Sarcoma
Soft Tissue Sarcoma (STS)
Notification to Implement Issued December 14, 2012
Stivarga (GIST) Regorafenib Other
Gastrointestinal Stromal Tumours
Notification to Implement Issued May 20, 2014
Gazyva Obinutuzumab Lymphoma
Follicular Lymphoma
Notification to Implement Issued June 19, 2017
Inlyta (RFA) Axitinib Genitourinary
Metastatic Renal Cell Carcinoma
Notification to Implement Issued June 30, 2017
Kisqali Ribociclib Breast
Advanced or Metastatic Breast Cancer
Notification to Implement Issued May 3, 2018
Lonsurf Trifluridine and Tipiracil Gastrointestinal
Metastatic Colorectal Cancer
Notification to Implement Issued July 23, 2018
Alecensaro Alectinib Lung
Non-Small Cell Lung Cancer (first line)
Notification to Implement Issued August 13, 2018
Stivarga Regorafenib Gastrointestinal
Unresectable Hepatocellular Carcinoma (HCC)
Notification to Implement Issued May 3, 2018
Lenvima Lenvatinib Genitourinary
Renal Cell Carcinoma (RCC)
Open for Feedback on Recommendation November 1, 2018
Tagrisso Osimertinib Lung
Non-Small Cell Lung Cancer
Notification to Implement Issued May 19, 2017
Opdivo Nivolumab Genitourinary
Metastatic Renal Cell Carcinoma
Notification to Implement Issued September 19, 2016
Opdivo & Yervoy in combo Nivolumab & Ipilimumab in combo Skin and Melanoma
Metastatic Melanoma
Notification to Implement Issued December 18, 2017
Blincyto Blinatumomab Leukemia
Pediatric Acute Lymphoblastic Leukemia (ALL)
Notification to Implement Issued September 8, 2017
Rydapt Midostaurin Leukemia
Acute Myeloid Leukemia
Notification to Implement Issued January 11, 2018
Zykadia Ceritinib Lung
Metastatic Non-Small Cell Lung Cancer
Notification to Implement Issued December 18, 2015
Opdivo Nivolumab Skin and Melanoma
Metastatic Melanoma
Notification to Implement Issued April 18, 2016
Ibrance Resubmission Palbociclib Breast
Advanced Breast Cancer
Notification to Implement Issued December 6, 2016
TBD Abemaciclib Breast
Advanced or metastatic breast cancer
Pending November 5, 2018
Folotyn Pralatrexate Lymphoma
Peripheral T-Cell Lymphoma (PTCL)
Under Review November 7, 2018
Keytruda Pembrolizumab Lymphoma
classical Hodgkin Lymphoma (cHL)
Notification to Implement Issued January 22, 2018
Afinitor Everolimus Breast
Advanced Breast Cancer
Notification to Implement Issued April 11, 2013
Erivedge Vismodegib Skin and Melanoma
Advanced Basal Cell Carcinoma
Notification to Implement Issued January 27, 2014
Istodax Romidepsin Lymphoma
Peripheral T-Cell Lymphoma
Notification to Implement Issued June 26, 2015
Pomalyst Pomalidomide Myeloma
Multiple Myeloma
Notification to Implement Issued August 18, 2014
Tafinlar & Mekinist in combo Dabrafenib & Trametinib in combo Skin and Melanoma
Metastatic Melanoma
Notification to Implement Issued September 29, 2015
Xalkori Crizotinib Lung
Advanced Non-Small Cell Lung Cancer
Notification to Implement Issued Original Submission Complete October 22, 2012
Treanda Bendamustine hydrochloride Lymphoma
Non-Hodgkin lymphoma (NHL)
Notification to Implement Issued December 14, 2012
Stivarga Resubmission (CRC) Regorafenib Gastrointestinal
Metastatic Colorectal Cancer
Notification to Implement Issued September 29, 2015
Zaltrap Aflibercept Gastrointestinal
Metastatic Colorectal Cancer
Notification to Implement Issued September 23, 2014
Yervoy Ipilimumab Skin and Melanoma
Advanced Melanoma
Notification to Implement Issued May 18, 2012
Sylvant Siltuximab Lymphoma
Multicentric Castleman's Disease (MCD)
Notification to Implement Issued July 8, 2015
Caprelsa Vandetanib Endocrine
Medullary Thyroid Cancer
Notification to Implement Issued April 17, 2017
Zykadia (Resubmission) Ceritinib Lung
Non-Small Cell Lung Cancer
Notification to Implement Issued April 5, 2017
Tecentriq Atezolizumab Lung
Non-Small Cell Lung Cancer
Notification to Implement Issued July 6, 2018
Lartruvo Olaratumab Sarcoma
Advanced Soft Tissue Sarcoma (STS)
Notification to Implement Issued May 3, 2018
Cotellic Cobimetinib Skin and Melanoma
Metastatic Melanoma
Notification to Implement Issued July 18, 2016
Yondelis Trabectedin Sarcoma
Metastatic Liposarcoma or Leiomyosarcoma
Notification to Implement Issued August 22, 2016
Lenvima Lenvatinib Endocrine
Differentiated Thyroid Cancer
Notification to Implement Issued October 5, 2016
Kyprolis (with lenalidomide) Carfilzomib (with lenalidomide) Myeloma
Multiple Myeloma
Notification to Implement Issued November 11, 2016
Keytruda Pembrolizumab Skin and Melanoma
Metastatic Melanoma
Notification to Implement Issued December 1, 2015
Imbruvica Ibrutinib Leukemia
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (previously untreated)
Notification to Implement Issued November 18, 2016
Imbruvica Ibrutinib Lymphoma
Waldenstrom's Macroglobulinemia
Notification to Implement Issued November 18, 2016
Venclexta Venetoclax Leukemia
Chronic Lymphocytic Leukemia (with 17p deletion)
Withdrawn January 10, 2017
Darzalex Daratumumab Myeloma
Multiple Myeloma (second-line or beyond)
Notification to Implement Issued October 24, 2017
Keytruda Pembrolizumab Genitourinary
Metastatic Urothelial Carcinoma
Notification to Implement Issued March 19, 2018
Opdivo Nivolumab Skin & Melanoma
Melanoma Adjuvant Therapy
Under Review October 19, 2018
Venclexta in combo Rituximab Venetoclax Leukemia
Chronic Lmphocytic Leukemia (CLL)
Under Review November 9, 2018
Imfinzi Durvalumab Lung
Non-Small Cell Lung Cancer
Under Review November 14, 2018
Opdivo Nivolumab Lymphoma
classical Hodgkin Lymphoma after failure of ASCT
Notification to Implement Issued May 22, 2018
Opdivo in combination with Yervoy Nivolumab in combination with Ipilimumab Genitourinary
Renal Cell Carcinoma
Notification to Implement Issued November 16, 2018
Erleada Apalutamide Genitourinary
Castrate Resistant Prostate Cancer
Notification to Implement Issued November 16, 2018
Abraxane Nab-paclitaxel Gastrointestinal
Metastatic Pancreatic Cancer
Notification to Implement Issued October 8, 2014
Alimta Pemetrexed Lung
Advanced Non-Squamous Non Small Cell Lung Cancer
Notification to Implement Issued December 5, 2013
Gazyva Obinutuzumab Leukemia
Chronic Lymphocytic Leukemia
Notification to Implement Issued June 26, 2015
Jakavi Ruxolitinib Other
Myelofibrosis
Notification to Implement Issued January 30, 2013
Mekinist Trametinib Skin and Melanoma
Metastatic Melanoma
Notification to Implement Issued November 6, 2013
Yervoy Ipilimumab Skin and Melanoma
First Line Advanced Melanoma
Notification to Implement Issued January 15, 2015
Zelboraf Vemurafenib Skin and Melanoma
Advanced Melanoma
Notification to Implement Issued August 1, 2012
Trisenox Arsenic Trioxide Leukemia
Acute Promyelocytic Leukemia
Notification to Implement Issued February 18, 2014
Tafinlar Dabrafenib Skin and Melanoma
Metastatic Melanoma
Notification to Implement Issued December 20, 2013
Xalkori Crizotinib Lung
Advanced Non-Small Cell Lung Cancer
Notification to Implement Issued Original Submission Complete June 17, 2013
Proleukin Aldesleukin (IL-2) Skin and Melanoma
In-transit Melanoma
Notification to Implement Issued July 31, 2015
Iclusig Ponatinib Leukemia
Chronic Myeloid Leukemia/ Acute Lymphoblastic Leukemia
Notification to Implement Issued October 20, 2015
Cyramza Ramucirumab Gastrointestinal
Metastatic Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma
Notification to Implement Issued November 13, 2015
Zydelig Idelalisib Leukemia
Chronic Lymphocytic Leukemia
Notification to Implement Issued September 2, 2015
Revlimid Lenalidomide Myeloma
Multiple Myeloma (newly diagnosed)
Notification to Implement Issued December 18, 2015
Ibrance Palbociclib Breast
Advanced Breast Cancer
Suspended July 25, 2016
Avastin Bevacizumab Gynecology
Platinum-Resistant Ovarian Cancer
Notification to Implement Issued August 15, 2016
Lynparza Olaparib Gynecology
Ovarian Cancer
Notification to Implement Issued October 17, 2016
Cyramza Ramucirumab Lung
Non-Small Cell Lung Cancer
File-Closed Not Submitted May 20, 2016
Alecensaro Alectinib Lung
Non-Small Cell Lung Cancer (with CNS metastases)
Notification to Implement Issued May 19, 2017
Blincyto (Resubmission) Blinatumomab Leukemia
Adult Acute Lymphoblastic Leukemia (ALL)
Notification to Implement Issued September 18, 2017
Keytruda Pembrolizumab Lung
Non-Small Cell Lung Cancer (Second Line or Beyond)
Notification to Implement Issued November 18, 2016
Adcetris Brentuximab Vedotin Lymphoma
Hodgkin’s Lymphoma at high risk of relapse or progression post-ASCT
Notification to Implement Issued March 8, 2018
TBD Cabozantinib Genitourinary
Renal Cell Carcinoma (RCC)
Withdrawn January 25, 2018
Venclexta Venetoclax Leukemia
Chronic Lymphocytic Leukemia
Notification to Implement Issued March 19, 2018
Keytruda Pembrolizumab Lung
Non-Small Cell Lung Carcinoma (First Line)
Notification to Implement Issued September 8, 2017
Avastin Bevacizumab Lung
Malignant Pleural Mesothelioma
Withdrawn April 11, 2017
Rituxan Rituximab Leukemia
Acute Lymphoblastic Leukemia
Notification to Implement Issued September 18, 2017
Onivyde Irinotecan Liposome Gastrointestinal
Metastatic Pancreatic Cancer
Notification to Implement Issued January 22, 2018
Faslodex Fulvestrant Breast
Locally Advanced or Metastatic Breast Cancer
Notification to Implement Issued February 16, 2018
Alunbrig Brigatinib Lung
Non-Small Cell Lung Cancer (NSCLC)
Pending November 7, 2018
Besponsa Inotuzumab Ozogamicin Leukemia
Acute Lymphoblastic Leukemia (ALL)
Notification to Implement Issued July 23, 2018
Mvasi Bevacizumab Gastrointestinal / Lung
Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar
Under Review October 19, 2018
Cabometyx Cabozantinib Genitourinary
Renal Cell Carcinoma
Under Review October 9, 2018
Blincyto Blinatumomab Leukemia
Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL)
Under Review October 24, 2018
Xtandi Enzalutamide Genitourinary
Non-metastatic castration-resistant prostate cancer
Under Review October 10, 2018
Adcetris (Resubmission) Brentuximab Vedotin Lymphoma
Hodgkin Lymphoma
Under Review October 24, 2018
Beleodaq Belinostat Lymphoma
Peripheral T-Cell Lymphoma (PTCL)
Withdrawn October 24, 2018
Tagrisso Osimertinib Lung
Non-Small Cell Lung Cancer (first line)
Open for Feedback on Recommendation November 1, 2018